Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1956 2
1957 1
2003 2
2010 1
2011 2
2012 2
2013 3
2014 1
2015 1
2016 1
2017 2
2018 2
2019 1
2020 4
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

25 results
Results by year
Filters applied: . Clear all
Page 1
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
Panoutsopoulou K, Avgeris M, Magkou P, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Loverix L, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A. Panoutsopoulou K, et al. Among authors: obermayr e. Int J Cancer. 2020 Dec 15;147(12):3560-3573. doi: 10.1002/ijc.33182. Epub 2020 Aug 1. Int J Cancer. 2020. PMID: 32621752
Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer.
Kasimir-Bauer S, Roder J, Obermayr E, Mahner S, Vergote I, Loverix L, Braicu E, Sehouli J, Concin N, Kimmig R, Net L, Roder H, Zeillinger R, Aust S, On Behalf Of The Ovcad Ovarian Cancer Diagnosis Initiative. Kasimir-Bauer S, et al. Among authors: obermayr e. Cancers (Basel). 2020 Sep 4;12(9):2519. doi: 10.3390/cancers12092519. Cancers (Basel). 2020. PMID: 32899818 Free PMC article.
Gene Expression of Kallikreins in Breast Cancer Cell Lines.
Watrowski R, Castillo-Tong DC, Obermayr E, Zeillinger R. Watrowski R, et al. Among authors: obermayr e. Anticancer Res. 2020 May;40(5):2487-2495. doi: 10.21873/anticanres.14219. Anticancer Res. 2020. PMID: 32366393
miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study.
Panoutsopoulou K, Avgeris M, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Vanderstichele A, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A. Panoutsopoulou K, et al. Among authors: obermayr e. Carcinogenesis. 2020 Jun 17;41(4):442-451. doi: 10.1093/carcin/bgz163. Carcinogenesis. 2020. PMID: 31586203
Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study.
Maritschnegg E, Heitz F, Pecha N, Bouda J, Trillsch F, Grimm C, Vanderstichele A, Agreiter C, Harter P, Obermayr E, Vergote I, Zeillinger R, Speiser P. Maritschnegg E, et al. Among authors: obermayr e. Int J Gynecol Cancer. 2018 Nov;28(9):1692-1698. doi: 10.1097/IGC.0000000000001361. Int J Gynecol Cancer. 2018. PMID: 30376484 Free PMC article.
Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.
Gostner JM, Obermayr E, Braicu IE, Concin N, Mahner S, Vanderstichele A, Sehouli J, Vergote I, Fuchs D, Zeillinger R. Gostner JM, et al. Among authors: obermayr e. Gynecol Oncol. 2018 May;149(2):371-380. doi: 10.1016/j.ygyno.2018.02.020. Epub 2018 Mar 9. Gynecol Oncol. 2018. PMID: 29530331
Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium.
Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C, Zeillinger R, Brandt B. Obermayr E, et al. Oncotarget. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017 Dec 5. Oncotarget. 2017. PMID: 29290959 Free PMC article.
25 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page